Watch CUE. Know when insiders buy.
One email the day a filing lands. Free.
CUE
Cue Biopharma, Inc.
28.00
−2.50 −8.20%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
67
PASS · shorts 67
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $203.4MP/E —DIV YIELD —FCF YIELD -24.66%REV TTM $37.7M +354.4%NET INCOME −$164.1MNET CASH $16.4M52W 5.31 – 36.78SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $7.9M | +166.7% | — | −$87.7M | −$153.1M | — | -24.14 | −$29M | $0 | −$29M | Aug 14 |
| Q1 2026 · Mar 31 | $5.7M | +1250.6% | — | −$5.4M | −$5.2M | — | -1.08 | −$10.9M | $121K | −$11.1M | May 14 |
| Q4 2025 · Dec 31derived | $21.9M | +1292.3% | — | $2M | $1.6M | — | 0.03 | −$1.1M | $0 | −$1.1M | Mar 16 |
| Q3 2025 · Sep 30 | $2.1M | −35.6% | — | −$7.6M | −$7.4M | — | -0.07 | −$9M | $0 | −$9M | Nov 12 |
| Q2 2025 · Jun 30 | $3M | +11.1% | — | −$8.6M | −$8.5M | — | -2.67 | −$3.4M | $27K | −$3.4M | Aug 14 |
| Q1 2025 · Mar 31 | $421K | −75.5% | — | −$12.3M | −$12.3M | — | -4.95 | −$8.2M | $150K | −$8.3M | May 14 |
| Q4 2024 · Dec 31derived | $1.6M | −13.5% | — | −$9.6M | −$9.5M | — | -0.10 | −$9M | $2K | −$9M | Mar 16 |
| Q3 2024 · Sep 30 | $3.3M | +58.9% | — | −$8.8M | −$8.7M | — | -0.17 | −$7.5M | −$1K | −$7.5M | Nov 12 |
| Q2 2024 · Jun 30 | $2.7M | — | — | −$10.4M | −$10.2M | — | -0.20 | −$10M | $10K | −$10M | Aug 12 |
| Q1 2024 · Mar 31 | $1.7M | — | — | −$12.7M | −$12.3M | — | -0.25 | −$9.8M | $55K | −$9.8M | May 12 |
| Q4 2023 · Dec 31derived | $1.8M | — | — | −$13.8M | −$13.4M | — | -0.29 | −$11M | $0 | −$11M | Mar 31 |
| Q3 2023 · Sep 30 | $2.1M | — | — | −$11.4M | −$11M | — | -0.24 | −$7.8M | $0 | −$7.8M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $27.5M | — | −$26.6M | −$26.6M | -96.9% | -0.28 | −$21.7M | $177K | −$21.9M | — | — |
| FY2024 · to Dec 31 | $9.3M | — | −$41.5M | −$40.7M | -438.0% | -0.72 | −$36.3M | $66K | −$36.4M | — | — |
| FY2023 · to Dec 31 | $5.5M | — | −$52.1M | −$50.7M | -924.1% | -1.11 | −$40M | $0 | −$40M | $0 | — |
| FY2022 · to Dec 31 | $1.2M | — | −$53.2M | −$53M | -4257.8% | -1.49 | −$41.8M | $171K | −$42M | $200K | — |
| FY2021 · to Dec 31 | $14.9M | — | −$43.7M | −$44.2M | -295.6% | -1.41 | −$38.8M | $913K | −$39.8M | $750K | — |
| FY2020 · to Dec 31 | $3.2M | — | −$45M | −$44.8M | -1419.8% | -1.56 | −$32.5M | $595K | −$33.1M | $271K | — |
Every number comes from Cue Biopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.